| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NexGel, Inc Common Stock$0.56
-0.08 (-13.21%)
Market Cap
6.33 M
EPS
-0.38
P/E Ratio
-1.5 $
Value Trade
33.02 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
2.65 M
Operating CF
-504.00 K
Total Assets
11.60 M
Total Liabilities
7.12 M
Equity
3.99 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.12 M
Monthly Burn
168.00 K
Runway
11.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.43 M
52 Week Range
0.56 - 3.02
% held by Insiders
22.57 %
% held by Institutions
5.49 %
Enterprise Value
8.79 M
Total Shares
8.14 M
Short %
1.71 %
Float Shares
6.25 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NXGL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NexGel, Inc Common Stock (NXGL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
NXGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NXGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NXGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NXGL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NXGL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-NXGL
May 6, 2026NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience , to Board of Directors Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment
NEXGEL, Inc. has appointed Brian Kieser and Kevin Harris from Sequence LifeScience to its Board of Directors. This move follows Sequence LifeScience's strategic investment of $5.5 million, which helped facilitate the acquisition of Celularity's degenerative disease segment. NEXGEL's CEO stated that the new board members bring valuable industry experience and a robust distribution system that can support the company's growth and innovation initiatives. The partnership is seen as a transformative opportunity for NEXGEL.
Read more →-NXGL
Apr 27, 2026NEXGEL Appoints Ian Blackman as Chief Financial Officer Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa.
NEXGEL, Inc. has appointed Ian Blackman as Chief Financial Officer to facilitate the integration of the acquisition of Celularity, enhancing the company's growth prospects. Blackman brings over 30 years of experience in finance and a strong track record in scaling businesses and handling complex transactions. His expertise is expected to be instrumental in advancing NEXGEL's strategic objectives, particularly in expanding its regenerative technology portfolio and improving financial performance. The leadership changes signal a focused effort to leverage Celularity's assets in the healthcare market.
Read more →-NXGL
Apr 21, 2026NEXGEL New Strategic Partner, Sequence LifeScience , Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment Transaction expected to approximately triple NEXGEL's annual reven
NEXGEL, Inc. has completed an acquisition of commercial-stage regenerative biomaterials from Celularity, facilitated by a $5.5 million investment from Sequence LifeScience. This acquisition is expected to significantly increase NEXGEL's annual revenue, potentially tripling it to approximately $35 million. Alongside this development, NEXGEL has launched BioNX Surgical, a division focused on advanced biomaterials aimed at regenerative medicine. The partnership with Sequence LifeScience is anticipated to enhance product development and commercialization capabilities.
Read more →-NXGL
Mar 10, 2026NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL's annual revenue to about $35 mi
NEXGEL has signed a definitive agreement with Celularity Inc. to license and acquire a transformative portfolio of commercial-stage regenerative biomaterial products. This transaction is projected to triple NEXGEL's annual revenue reaching approximately $35 million and to make the company immediately profitable upon closing. The acquired products focus on tendon repair, skin grafts, and bone growth, supported by existing insurance reimbursement pathways. The deal will also bring an experienced commercial team to NEXGEL, significantly enhancing its operational capabilities in the medical technology sector.
Read more →-NXGL
Feb 10, 2026NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence LANGHORNE, Pa.
NEXGEL, Inc. announced a financing commitment of $1.797 million aimed at a potential acquisition targeted for completion in the first quarter of 2026. This acquisition is contingent upon successful due diligence by both NEXGEL and the investor. The company has a history of successfully closing several acquisitions, indicating a potential for future growth. Additional funding of up to $14.869 million is possible, depending on the due diligence outcome.
Read more →-NXGL
Dec 11, 2025NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also rece
NEXGEL, Inc. has announced the spin-off of its drug delivery program into a new entity called NexGelRx, which focuses on Rx drug delivery solutions using proprietary hydrogel technology. Shareholders will benefit from a 19.99% non-dilutive equity interest and a 5% global royalty on products developed by NexGelRx. The funding for NexGelRx includes an initial investment from outside investors, allowing NEXGEL to concentrate on its core manufacturing and consumer branding operations. This strategic move aims to explore high-value drug delivery opportunities without incurring additional costs to NEXGEL.
Read more →-NXGL
Nov 11, 2025NEXGEL Reports Third Quarter 2025 Financial Results LANGHORNE, Pa.
NEXGEL, Inc. reported its third quarter 2025 financial results, revealing a net revenue of $2.93 million, which is slightly lower compared to the same quarter last year. The company's gross profit increased to $1.24 million, resulting in a gross profit margin of 42.4%. Although the net loss attributable to stockholders decreased, the adjusted EBITDA loss remained the same as the previous year. Management highlighted growth in the contract manufacturing sector and new product launches as key drivers for future success.
Read more →-NXGL
Aug 12, 2025NEXGEL Reports Second Quarter 2025 Financial Results Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter w
NEXGEL, Inc. reported its second quarter 2025 financial results, showcasing a substantial revenue increase of 100.3% from the previous year, totaling $2.88 million. The company's gross profit margin also improved significantly to 43.6%. Despite this growth, NEXGEL recorded a net loss of $0.67 million. The company reiterated its revenue guidance for the year at $13 million and expressed confidence in achieving positive EBITDA, bolstered by a recent $1 million advance from STADA to support product launches and marketing efforts.
Read more →-NXGL
Aug 5, 2025NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors LANGHORNE, Pa.
NEXGEL, a company specializing in high-water-content hydrogels, appointed Steve Ciardiello, CPA, as a new member of its Board of Directors. Ciardiello currently serves as the Chief Accounting Officer of Shutterstock and brings over 25 years of financial leadership experience. His extensive background in corporate governance and public company operations is anticipated to greatly assist NEXGEL in its growth strategy. The appointment is seen as a significant step forward for the company as it aims to enhance its impact in the healthcare sector.
Read more →-NXGL
Aug 1, 2025NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement LANGHORNE, Pa.
NEXGEL, Inc. announced a $950,000 registered direct offering and a concurrent private placement, involving the sale of 413,044 shares at $2.30 each. The company will also issue unregistered warrants for purchase of 206,522 shares at an exercise price of $4.25. The CEO emphasized that the financing, along with a recent $1 million non-dilutive advance, significantly bolsters the company's financial position in anticipation of high growth in the latter half of the year. These transactions are part of NEXGEL's strategy to enhance its working capital as it navigates a critical period.
Read more →-NXGL
Jul 14, 2025NEXGEL and STADA AG Announce Expansion of Partnership for North America LANGHORNE, Pa.
NEXGEL, Inc. has announced an expansion of its partnership with STADA Arzneimittel AG to launch new digestive enzyme formulas and skincare products targeting scars and stretch marks in North America. As part of the agreement, STADA will provide $1 million in financial support to NEXGEL to assist with product launches and marketing efforts. This collaboration demonstrates both companies' commitment to leveraging their strengths for innovative consumer health solutions across the region.
Read more →-NXGL
May 13, 2025NEXGEL Reports First Quarter 2025 Financial Results First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was
NEXGEL, Inc. (NASDAQ: NXGL) announced its financial results for the first quarter of 2025, reporting a revenue increase of 121% to $2.81 million compared to the same period in 2024. The company's gross profit margin also improved significantly to 42.4%, a notable increase from the prior year. Despite these positive financial highlights, NEXGEL still experienced a net loss of $0.71 million but noted a tightening of its EBITDA losses. The CEO expressed confidence in the company's ability to meet its revenue guidance of $13 million for 2025 and achieve positive EBITDA.
Read more →-NXGL
Mar 24, 2025NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year
NEXGEL, Inc. reported record financial results for the fourth quarter and full year 2024. The company achieved significant revenue growth, with fourth quarter revenue reaching $3.04 million, and full year revenue totaling $8.69 million, increases of 181% and 112% year-over-year, respectively. Despite these gains, NEXGEL incurred a net loss of $3.28 million for the year, slightly higher than the previous year's loss. Looking ahead, the company anticipates at least $13 million in revenue for 2025 and expects to achieve positive EBITDA.
Read more →-NXGL
Jan 22, 2025NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025 Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing gro
NEXGEL, Inc. has issued a letter to shareholders outlining positive revenue guidance for 2024 and 2025. The company expects Q4 2024 revenues to reach approximately $3.0 million, totaling around $8.6 million for the year, marking over 100% growth year-over-year. Looking into 2025, NEXGEL anticipates generating at least $13 million in revenue and achieving positive cash flow from operations. Additionally, the company highlights several growth areas, including contract manufacturing and new product launches, while acknowledging that current financial estimates are preliminary.
Read more →-NXGL
Jan 2, 2025NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer LANGHORNE, Pa.
NEXGEL, Inc. has appointed Joseph F. McGuire as its new Chief Financial Officer, effective January 1, 2025. McGuire brings over 30 years of experience, having previously worked with both private and public companies across various industries. His appointment is seen as a strategic move to support the company's growth. Adam Drapczuk III, the outgoing CFO, will continue with the company as a consultant moving forward.
Read more →-NXGL
Nov 13, 2024NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and
NEXGEL reported record revenues for Q3 2024, totaling $2.94 million, which marks a significant increase of 141% year-over-year and 104% compared to the previous quarter. The company achieved a gross profit margin of 43.6%, reflecting strong sales growth in branded consumer products and contract manufacturing. However, net losses rose to $754,000, although adjusted EBITDA losses improved. Looking forward, NEXGEL anticipates continued growth and a narrowing of losses in Q4 2024, supported by a successful financing round.
Read more →-NXGL
Nov 11, 2024NEXGEL Announces $2,000,000 Registered Direct Offering LANGHORNE, Pa.
NEXGEL, Inc. has announced a registered direct offering totaling $2 million, consisting of 727,272 shares of common stock and warrants for additional shares. The shares will be sold at a price of $2.75 each, while the warrants have an exercise price of $4.25. This financing is aimed at enhancing the company's balance sheet and supporting inventory and marketing efforts. NEXGEL has seen rapid growth due to new customer orders, which this funding will help maintain.
Read more →-NXGL
Oct 10, 2024NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially LANGHORNE, Pa.
NEXGEL, Inc. has preannounced its expected record revenue for the third quarter of 2024, estimated at approximately $2.85 million. This represents a year-over-year increase of about 133% and a quarter-over-quarter increase of around 98%. Additionally, branded consumer product sales have shown notable growth, particularly in the Silly George line, while the contract manufacturing segment is returning to more stable revenue levels. However, the company notes that these preliminary estimates are subject to change pending final financial reviews.
Read more →-NXGL
Aug 14, 2024NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million LANGHORNE, Pa.
NEXGEL, Inc. reported a record revenue of $1.44 million for the second quarter of 2024, reflecting a 23.4% increase compared to the same period last year. The growth was driven by strong sales from the recently acquired Silly George brand. The company reiterated its revenue guidance for upcoming quarters, projecting substantial growth ahead. However, NEXGEL faced increased operational costs and a net loss for the quarter, which highlights challenges alongside its achievements.
Read more →-NXGL
Aug 12, 2024NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders LANGHORNE, Pa.
NEXGEL, Inc. has announced a registered direct offering totaling $1,110,000, with significant participation from insiders, including management and board members. The offering includes 444,000 shares of common stock at $2.50 per share and warrants for purchasing additional common stock. Proceeds will be used to bolster working capital and meet increased demand following the acquisition of the Silly George brand. The company's CEO expressed optimism that this funding will strengthen their balance sheet as they look ahead to growth opportunities.
Read more →-NXGL
Jul 8, 2024NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively LANGHORNE, Pa.
NEXGEL, Inc. reported preliminary record revenue of $1.4 million for Q2 2024, marking a 20% increase year-over-year. The company anticipates further growth, projecting revenues of $2.2 million for Q3 and $2.6 million for Q4 2024, which represents substantial year-over-year increases. While the report cited lower revenues from CG Converting and Packaging due to a facility move, CEO Levy expressed optimism about the growth in contract manufacturing and the popularity of consumer brands like Silly George. However, the numbers are preliminary and subject to change as the company finalizes its financial results.
Read more →-NXGL
May 16, 2024NEXGEL Acquires International Beauty Brand, Silly George Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHO
NEXGEL has announced the acquisition of Silly George, a beauty brand specializing in eye and eyelash products, which has a revenue run rate of approximately $2 million. The acquisition is expected to provide operational synergies and moments for cross-brand marketing, capitalizing on Silly George's strong social media presence. With the deal structured at $400,000 in cash and stock, NEXGEL aims to leverage this addition to generate more revenue and drive profitability. The management of Silly George will remain in place to ensure continuity during the transition.
Read more →-NXGL
May 13, 2024NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa.
NEXGEL, Inc. reported a remarkable revenue growth of 104% year-over-year for the first quarter of 2024, totaling $1.27 million. This growth is attributed to notable increases in both their contract manufacturing and consumer branded product segments. Despite this strong performance, the company recorded a net loss of $905,000, reflecting rising general and administrative expenses. NEXGEL is preparing for further growth by expanding facilities and launching new products.
Read more →-NXGL
Apr 1, 2024NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year LANGHORNE, Pa.
NEXGEL, Inc. reported a substantial revenue increase of 99.7% for the full year of 2023, reaching $4.1 million, largely fueled by sales of branded products and contract manufacturing. The company has made significant strides in expanding its operational infrastructure and has secured strategic partnerships with major corporations like AbbVie and STADA. Additionally, NEXGEL is undergoing a significant facility expansion to support anticipated product demand, alongside a new joint venture for retail distribution. Despite a reduction in developmental expenses, the company reported a decreased loss compared to 2022, signaling improved financial health.
Read more →-NXGL
Feb 21, 2024NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders LANGHORNE, Pa.
NEXGEL, Inc. has announced a registered direct offering of $975,000 led by its insiders, including members of management and the Board of Directors. The offering includes 462,090 shares and warrants to purchase an additional 231,040 shares at a combined purchase price of $2.11 per share. The proceeds are intended to enhance working capital and support anticipated growth opportunities throughout the year. The transaction aligns with the company’s strategy following previous capital expenditures and acquisitions in 2023.
Read more →-NXGL
Dec 11, 2023NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America LANGHORNE, Pa.
NEXGEL, Inc. has entered into a partnership with STADA Arzneimittel AG to distribute and commercialize consumer health over-the-counter products in North America, aiming for a product launch in mid-2024. This collaboration leverages STADA's established European market presence, enhancing NEXGEL's footprint in the North American healthcare sector. NEXGEL specializes in high-water-content hydrogels and has been in operation for over two decades, with a diverse range of products under its brand. The strategic partnership signals potential growth opportunities for both companies in the consumer health market.
Read more →-NXGL
Dec 5, 2023NEXGEL Acquires Kenkoderm Psoriasis Skincare Line Acquisition expands NEXGEL's health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growt
NEXGEL, Inc. has acquired Kenkoderm, a skincare line that specializes in psoriasis treatment. This acquisition aims to enhance NEXGEL's product portfolio and is expected to contribute positively to its revenue and profitability. The integration of Kenkoderm’s products, which were developed to avoid the side effects of traditional treatments, aligns with NEXGEL’s health and wellness strategy. NEXGEL's CEO believes there are immediate synergies to improve marketing and supply chain operations. The move also opens up opportunities for further growth and market expansion.
Read more →-NXGL
Nov 13, 2023NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa.
NEXGEL, Inc. reported a record revenue of $1.2 million for the third quarter of 2023, marking a 115% increase compared to the previous year. The company's gross profit margin improved significantly to 28.2%, up from 15.0% in the second quarter of 2023, and the net loss continued to decline. Key factors driving this growth include enhanced contract manufacturing and partnerships with AbbVie and Enigma Health. The CEO expressed optimism about continued revenue growth and operational optimization as 2024 approaches.
Read more →-NXGL
Oct 30, 2023NEXGEL Secures Supply Agreement with AbbVie LANGHORNE, Pa.
NEXGEL has announced a supply agreement with AbbVie to supply gel pads for use with AbbVie's Rapid Acoustic Pulse device, aimed at improving the appearance of cellulite. This agreement highlights NEXGEL's proprietary hydrogel technology, which has been developed over two decades. The collaboration is seen as a significant achievement for NEXGEL, as noted by its CEO, Adam Levy. Additionally, the release includes a cautionary note about forward-looking statements and associated risks.
Read more →-NXGL
Aug 14, 2023NEXGEL Reports Second Quarter 2023 Record Revenue of $1.17 Million, an Increase of 108% Year-Over-Year LANGHORNE, Pa.
NEXGEL, Inc. reported a record revenue of $1.17 million for Q2 2023, marking a significant 108% year-over-year increase. This growth was primarily driven by a 174% surge in contract manufacturing sales and a 44% increase in branded products. Despite strategic investments aimed at enhancing capacity and meeting future demand, the company noted a decline in gross profit margin. Additionally, while NEXGEL's net loss improved compared to the same period last year, operating expenses saw an increase due to rising costs.
Read more →-NXGL
May 15, 2023NEXGEL Reports First Quarter 2023 Financial Results 2023 first quarter revenue increased 56.6% year-over-year to $620 thousand Approximately $5.8 million in cash and securities at
NEXGEL reported significant growth in its first quarter 2023 financial results, with revenue rising 56.6% year-over-year to $620 thousand. The company anticipates continued growth, projecting second quarter revenue of $1.0 million, buoyed by its joint venture with CG Labs and new product launches. However, it recorded an increased loss and wider gross margin loss compared to the previous year, raising some concerns. Despite these challenges, the acquisition of a joint venture and operational investments signal potential for future growth.
Read more →-NXGL
Mar 27, 2023NEXGEL Reports Fourth Quarter and Full Year 2022 Financial Results 2022 revenue increased 32% YoY to $2.05 million, while gross profit margin improved As of
NEXGEL, Inc. announced its financial results for Q4 and full year 2022, highlighting a 32% year-over-year revenue growth to $2.05 million. The company's gross profit margin improved to approximately 12.5%. Despite some challenges in the fourth quarter, including a slight revenue decline and increased net loss, NEXGEL is optimistic about its future, attributing growth to increased investments in R&D and successful new product launches. The company is also well-capitalized with over $6.6 million in cash and securities to support operations through 2025.
Read more →-NXGL
Mar 2, 2023NEXGEL Acquires 50% Interest in Newly Formed Joint Venture with C.G. Laboratories for Converting and Packaging Business Strategic investment in CG Labs' revenue generating and already profitable business increases NEXGEL
NEXGEL, Inc. has announced the acquisition of a 50% interest in a new joint venture named CG Converting and Packaging, LLC, established with C.G. Laboratories. This strategic investment is set to enhance NEXGEL's operational capacities by improving margins and streamlining its supply chain through established synergies. As CG Labs' converting and packaging division has been a long-term profitable customer for NEXGEL, this partnership aims to foster further growth and allow onboarding of new customers. NEXGEL is contributing $500,000 towards the joint venture for equipment upgrades.
Read more →-NXGL
Jan 17, 2023NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee LANGHORNE, Pa.
NEXGEL, Inc. has appointed Scott Henry, CFA, as an independent director on its Board and as a member of the Audit Committee, effective immediately. Henry brings over 20 years of experience within the pharmaceutical, biotechnology, and medical device sectors and has a strong background in investment analysis. The CEO expressed confidence in Henry's ability to support the company's growth initiatives due to his network and knowledge of small and microcap companies. NEXGEL sees this appointment as a strategic move to capitalize on its market potential.
Read more →-NXGL
Dec 7, 2022NEXGEL Announces Share Repurchase Program LANGHORNE, Pa.
Announces Share Repurchase Program Pa. - December 7, 2022 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that its Board of Dire
Read more →-NXGL
Nov 8, 2022NEXGEL Reports Third Quarter 2022 Financial Results Revenue increased 69.6% YoY while gross profit margin improved both sequentially and YoY to 26% LANGHORNE, Pa.
Reports Third Quarter 2022 Financial Results increased 69.6% YoY while gross profit margin improved both sequentially and YoY to 26% Pa. - November 8, 2022 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydro
Read more →-NXGL
Aug 10, 2022NEXGEL Reports Second Quarter 2022 Financial Results Second quarter 2022 revenue increased 35% YoY and 42% sequentially to $561 Thousand Company sees growth in its branded consumer products and launches MEDAGEL Pro Pads
Reports Second Quarter 2022 Financial Results quarter 2022 revenue increased 35% YoY and 42% sequentially to $561 Thousand sees growth in its branded consumer products and launches MEDAGEL Pro Pads Pa. - August 10, 2022 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL
Read more →-NXGL
May 12, 2022NEXGEL Reports First Quarter 2022 Financial Results First quarter 2022 revenue increased 48% YoY to $396 Thousand Company launched two new consumer OTC products using its HYDROGEL Technology: The MEDAGEL ClearComfort Hyd
Reports First Quarter 2022 Financial Results First quarter 2022 revenue increased 48% YoY Company launched two new consumer OTC products using its HYDROGEL Technology: The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch LANGHORNE, Pa. - May 12, 2022
Read more →-NXGL
Mar 21, 2022NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results Full year 2021 revenue increased 130% YoY to $1.55 million As of
Reports Fourth Quarter and Full Year 2021 Financial Results Full year 2021 revenue increased 130% YoY to As of December 31, 2021, the Company had $13.35 LANGHORNE, Pa. - March 21, 2022 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-ge
Read more →-NXGL
Jan 12, 2022NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch - ClearComfort Patches Prevent and Treat Blisters Using Advanced Hydrogel Technology - LANGHORNE, Pa.
NEXGEL Announces the Launch of MEDAGEL ClearComfort - ClearComfort Patches Prevent and Treat Blisters Using Advanced Hydrogel Technology - LANGHORNE, Pa. - January 12, 2022 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, hi
Read more →-NXGL
Dec 31, 2021NEXGEL Provides 2021 Year in Review Significant progress developing and identifying innovative hydrogel applications across consumer and medical uses culminating in December 2021 IPO As of
Significant progress developing and identifying innovative hydrogel applications across consumer and medical uses culminating in December 2021 IPO 31, 2021, NEXGEL had approximately $13.3 Million cash to advance its programs as part of its growth strategy PA. - January 10, 202
Read more →-NXGL
Dec 21, 2021NexGel, Inc. Announces Listing on Nasdaq and Pricing of $14.2 Million Initial Public Offering LANGHORNE, PA
Inc. Announces Listing on Nasdaq and Pricing of $14.2 Million Initial Public Offering December 21, 2021 - NexGel, Inc. ("NexGel" or the "Company") (Nasdaq:NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used f
Read more →-NXGL
Sep 9, 2021NEXGEL Announces Appointment of Miranda Toledano to Board of Directors Ms. Toledano Brings Over Two Decades of Biopharmaceutical Wall Street Experience to
NEXGEL Announces Appointment of Miranda Toledano to Board of Directors Ms. Toledano Brings Over Two Decades of Biopharmaceutical Wall Street Experience to NEXGEL LANGHORNE, Pa. - September 9, 2021 - NEXGEL, Inc. ("NEXGEL" or the "Company"), a leading provider of ultra-gentle
Read more →-NXGL
Jul 22, 2021NEXGEL Reports Preliminary Second Quarter 2021 Financial Results and Provides Corporate Update LANGHORNE, Pa.
Reports Preliminary Second Quarter 2021 Financial Results and Provides Corporate Update LANGHORNE, Pa. - July 22, 2021 - NEXGEL, Inc. ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today a
Read more →-NXGL
Jun 1, 2021NEXGEL Appoints Adam Drapczuk as Chief Financial Officer Mr. Drapczuk Brings Nearly Two Decades of Healthcare Experience to NEXGEL, Successfully Leading Companies Through the IPO Process to Full-Scale Commercialization L
Appoints Adam Drapczuk as Chief Financial Officer Brings Nearly Two Decades of Healthcare Experience to NEXGEL, Successfully Leading Companies Through the IPO Process to Full-Scale Commercialization LANGHORNE, Pa. - June 1, 2021 - NEXGEL, Inc. ("NEXGEL" or the "Company"), a le
Read more →-NXGL
May 29, 2020NEXGEL, Inc.
E-mail: investors@nexgel.com NEXGEL, Inc. Announces the Acquisition Sport Defense LLC Product Line PA - NEXGEL, Inc. ("NEXGEL") announces the acquisition of Sport Defense LLC's ("Sport Defense") line of products. This strategic acquisition allows NEXGEL to vertically integrat
Read more →-NXGL
Apr 3, 2020NEXGEL, Inc. Announces the Appointment of Dr. Jerome Zeldis its Board of Directors NEXGEL, Inc. ("NEXGEL" or the "Company"), an innovative Company developing ultra-gentle, high-water content E-beam hydrogels with a focus
NEXGEL, Inc. Announces the Appointment of Dr. Jerome Zeldis its Board of Directors NEXGEL, Inc. ("NEXGEL" or the "Company"), an innovative Company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the Consumer OTC, Rx, Medical Device and Cosmetic ma
Read more →-NXGL
Jun 21, 2019AquaMed Releases Letter to Stockholders To the New Stockholders of AquaMed Technologies, Inc.: I am pleased to announce that on Friday
AquaMed Releases Letter to Stockholders To the New Stockholders of AquaMed Technologies, Inc.: I am pleased to announce that on Friday, June 21, 2019, Adynxx, Inc. ("Adynxx") effected the distribution of all outstanding shares of AquaMed Technologies, Inc. ("AquaMed" or the "Co
Read more →Competitive Position
How NXGL ranks across every disease it competes inCompetitive Position is a premium feature
See how NXGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial